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ABSTRACT  
 
Background Whether patients who are resected for ampullary adenocarcinoma have a survival 
benefit from adjuvant chemotherapy is currently not known. The aim of this study was to compare 
propensity score-matched survival between patients with and without adjuvant chemotherapy after 
resection of ampullary adenocarcinoma. 
 
Methods  An international multicentre cohort study was conducted, including patients who 
underwent pancreatoduodenectomy for ampullary adenocarcinoma (2006-2017) in 13 centres in six 
countries. Propensity scores were used to match patients who received adjuvant chemotherapy to 
those who did not; both in the entire cohort and in two subgroups (pancreaticobiliary/mixed and 
intestinal subtype). Survival was assessed using the Kaplan-Meier method and Cox regressions.  
 
Results  Overall, 1163 patients underwent pancreatoduodenectomy for ampullary adenocarcinoma. 
After excluding 179 patients, median survival in the resulting 976 patients was 67 months (95 per cent 
confidence interval 56-78), of which a total of 520 (53 per cent) patients received adjuvant 
chemotherapy. In a propensity-matched cohort (194 vs 194 patients), median survival was better after 
adjuvant chemotherapy compared to those without adjuvant chemotherapy (median survival not 
reached vs 60 months, respectively; p=0.051). In the pancreaticobiliary/mixed subtype a survival 
benefit was seen; median survival was not reached in patients receiving adjuvant chemotherapy vs 32 
months in the group without chemotherapy, p=0.020. The intestinal subtype did not show survival 
benefit from adjuvant chemotherapy. 
 
Conclusions  Patients with resected ampullary adenocarcinoma may benefit from gemcitabine-
based adjuvant chemotherapy, but this effect may be reserved for those with the pancreaticobiliary 
and/or mixed subtype. 
 
 
 
 
 
 
INTRODUCTION 
Ampullary adenocarcinoma accounts for seven per cent of pancreatic head and periampullary cancers 
and 0.2 per cent  - 0.5 per cent of all gastro-intestinal cancers1–3. Ampullary adenocarcinoma arises 
from the ampulla of Vater, the confluence of the common bile duct and the pancreatic duct, or from 
the papilla of Vater, the protrusion of the ampulla of Vater into the duodenum4–6 (Figure 1).  
Compared with other periampullary cancers, ampullary adenocarcinoma often presents at an earlier 
stage, as a result of biliary obstruction7. Therefore, ampullary adenocarcinoma is generally more 
amenable to resection at the time of diagnosis, resulting in higher resection rates compared with other 
periampullary cancers (resection rates of 50 per cent vs 20 per cent, respectively)8,9. Moreover, 
patients with ampullary adenocarcinoma have a better prognosis, with 5-year survival rates varying 
from 30% to 70% after resection1,9–13. Despite this more favourable profile, the majority of patients 
with ampullary adenocarcinoma will eventually succumb to recurrent disease14.  
Given the rarity of ampullary adenocarcinomas, no single randomized clinical trial in adjuvant 
treatment has focused specifically on ampullary adenocarcinoma. The most recent high-level evidence 
concerning adjuvant chemotherapy in ampullary adenocarcinoma derives from the ESPAC-3 trial, 
which was conducted in patients with pancreatic head and periampullary cancer and including 
ampullary adenocarcinoma as a subgroup. Consequently, the subgroup analysis in this study was likely 
to be underpowered (e.g. only 297 patients with ampullary adenocarcinoma)15. Additionally, there is 
extensive heterogeneity within ampullary adenocarcinoma due to the different epitheliums from 
which ampullary adenocarcinoma may arise, which results in different histopathologic subtypes 
(intestinal, pancreaticobiliary and mixed type)6,16. At present, it is unclear whether these subtypes gain 
a survival benefit from adjuvant chemotherapy.  
The aim of this study is to investigate the potential survival benefit of adjuvant chemotherapy in the 
different subtypes of resected ampullary adenocarcinoma by matching patients who received 
adjuvant chemotherapy to those who did not, using propensity scores.   
 
Figure 1. Anatomy of the ampulla of Vater 
  
METHODS 
Study design and setting 
An international retrospective multicentre cohort study was performed. Patients were included from 
13 tertiary referral centres in six countries involving Europe and the United States (participating 
centres and corresponding patient contribution are presented in supplementary Table S1). The study 
was based on an anonymized database, according to the Health Research Authority in the United 
Kingdom, both Research Ethics Committee and Health Research Authority approval are not required 
for research databases, this includes the release of non-identifiable data for analysis. Due to the 
retrospective nature of the study, written informed consent was not obtained17. This study is reported 
in accordance with The Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) statement18. 
 
Eligibility and data collection 
Included were adults who underwent elective pancreatoduodenectomy for ampullary 
adenocarcinoma, with curative intent, between January 1, 2006 and December 31, 2017. Excluded 
were patients in whom it was unknown whether they received adjuvant chemotherapy, patients who 
died perioperatively, patients who received adjuvant radiotherapy and those with incomplete follow 
up data, which was defined as either missing vital status or no further follow-up beyond discharge 
after surgery. Clinical and histopathologic data were collected from electronic patient files.  
Demographic variables included age, sex, body-mass-index (BMI) and American Society of 
Anaesthesiologists (ASA) classification. Histopathologic variables were collected from histology 
reports and included histopathologic subtype (intestinal, pancreaticobiliary or mixed), resection 
margin status, differentiation grade, pT-stage, pN-stage, pM-stage, perineural invasion and 
lymphovascular invasion.  
Resection specimens were evaluated by certified pathologists and results documented per local 
protocol19. TNM staging was according to the 7th edition of the American Joint Committee on Cancer 
(AJCC)20. Resections were considered margin-negative if no tumour cells were found within 1mm of 
each microscopically assessed margin, according to the definition of the Royal College of 
Pathologists19.  
Referral for adjuvant chemotherapy was based on consensus of the local multi-disciplinary team. 
Advice on adjuvant chemotherapy and regimen was at discretion of the treating oncologist.  
 
 
 
 Outcome 
The primary outcome of this study was overall survival, defined as the time in months between date 
of surgery and date of death, or censored at the date of last follow-up. The date of last follow-up was 
defined by the date of the last visit of each patient.  
 
Histopathologic subtypes 
Classification of intestinal and pancreaticobiliary subtype was according to the 4th edition of the World 
Health Organization (WHO) classification for tumours of the digestive system21. The intestinal type of 
ampullary adenocarcinoma arises from the adjacent duodenal mucosa and is characterized by 
cribriforming tubular glands with central necrosis, histologically resembling colonic adenocarcinoma. 
Pancreaticobiliary type ampullary adenocarcinoma derives from the terminal pancreatic or biliary 
ducts and is characterized by simple or branching glands within a desmoplastic stroma. Mixed type 
ampullary adenocarcinoma are occasionally encountered and show a combination of intestinal and 
pancreaticobiliary type morphology.  
Reporting of ampullary adenocarcinoma was either performed according to the protocol of the Royal 
College of Pathologist19, the College of American Pathologist22 (both use the WHO classification), or 
according to a local protocol based on the WHO classification. Classification of histopathologic subtype 
was primary done based on morphology. Immunohistochemistry was not routinely performed, but on 
occasion only.     
 
Propensity score matching 
Propensity scores were used to match patients who received adjuvant chemotherapy to patients who 
did not receive adjuvant chemotherapy. Matching was performed on the complete cohort and on two 
subgroups, the pancreaticobiliary/mixed subtype and the intestinal subtype. The decision to merge 
the pancreaticobiliary and mixed subtype is a result of the most frequently administered 
chemotherapy (Gemcitabine) for these subtypes. The rationale for this was that patients with the 
mixed subtype might benefit from a gemcitabine-based regimen because a proportion of the tumour 
(the pancreaticobiliary-type cells) could potentially respond to such a regimen.  
Propensity scores were obtained from a logistic regression model and included variables that were 
expected to affect survival, including: age, ASA classification, T-class, N-class, overall stage, resection 
margin status, differentiation grade, lymphovascular invasion and perineural invasion.  
Matching was performed on a nearest neighbour basis, in a 1:1 ratio without replacement, with a 
calliper width of 0.01 in the complete cohort and with a calliper width of 0.02 in the two subgroups. 
Balance was assessed using the standardized mean difference (SMD). Optimal balance is achieved 
when SMD is 0.1 or below23.  
 
Statistical analysis 
Data were analysed using SPSS® 24.0 software (SPSS, Chicago, IL, USA). Categorical data are presented 
as counts with proportions and continuous data as means with standard deviations (SD) or, medians 
with interquartile ranges (IQR), as appropriate. Categorical data were compared using the Chi Square-
test, whereas continuous data were compared by the Student’s t-test for normally distributed data 
and non-normally distributed data by its nonparametric equivalent the Mann-Whitney U test.  
Overall survival was assessed in both the unmatched and matched cohort. In the unmatched cohort 
uni- and multivariable Cox proportional hazards models were performed. The independent variable in 
this model was adjuvant chemotherapy, whereas, the dependent variable was overall survival. A 
potential causal effect of adjuvant chemotherapy on overall survival is assumed.  
All variables that were considered potential confounders were entered in the univariable analysis, 
variables with a p value <0.1 were entered in the multivariable model and stepwise backward selection 
was applied to remove further variables from the model. Adjuvant chemotherapy, as being the 
variable of interest, was forced into the model regardless of the P-value. In addition, to assess whether 
the effect of adjuvant chemotherapy differs between lymph node negative and - positive patients, the 
interaction term pN-stage*Adjuvant chemotherapy was added to the Cox model. Pre-specified 
subgroup analyses were performed for the pancreaticobiliary/mixed subtype and for the intestinal 
subtype. The Kaplan-Meier method and log rank test were used to assess overall survival in the various 
matched cohorts. A P-value <0.050 was considered statistically significant.  
 
RESULTS  
Overall, 1163 patients underwent pancreatoduodenectomy for ampullary adenocarcinoma during the 
study period. Several patients did not meet the eligibility criteria as shown in the flowchart (Figure 2), 
either due to perioperative mortality (n=44, 3.8 per cent of patients), 105 (9.0 per cent) due to 
unknown receipt of adjuvant chemotherapy, 30 (2.6 per cent) patients due to receipt of adjuvant 
radiotherapy and 8 patients (0.7 per cent) due to incomplete follow-up.  
All clinical and histopathologic characteristics of the unmatched and matched cohort are reported in 
Table 1. A total of 520 patients received adjuvant chemotherapy, whereas 456 patients did not. The 
adjuvant chemotherapy regimen was known in 515 of the 520 patients.  
 
Table 1. Baseline characteristics of the unmatched and matched cohort of patients with resected AAC. 
 Unmatched cohort Matched cohort 
 Adjuvant 
chemotherapy 
(N=520) 
No adjuvant 
chemotherapy 
(N=456) 
SMD P value Adjuvant 
chemotherapy 
(N=194) 
No adjuvant 
chemotherapy 
(N=194) 
SMD P value 
Age, years (SD) 64 (10) 69 (10) 0.50 <0.001 69 (9) 68 (10) 0.01 0.564 
Femalea 219 (42.2) 201 (44.3) 0.04 0.514 76 (39.2) 93 (47.9) 0.20 0.082 
ASA classification (%)b 
  1 
  2 
  3 
  4 
 
71 (17.7) 
237 (59.1) 
89 (22.2) 
4 (1.0) 
 
54 (15.3) 
205 (58.2) 
91 (25.9) 
2 (0.6) 
0.08 0.544  
27 (13.9) 
111 (57.2) 
55 (28.4) 
1 (0.5) 
 
28 (14.4) 
121 (62.4) 
44 (22.7) 
1 (0.5) 
0.10 0.643 
BMI, kg/m2 (SD)c 25.9 (4.4) 25.8 (4.7) 0.02 0.762 25.6 (4.1) 25.6 (4.6) 0.00 0.983 
Resection margind 
  R0 
  R1 
 
393 (75.9) 
125 (24.1) 
 
388 (85.5) 
66 (14.5) 
0.35 <0.001  
146 (75.3) 
48 (24.7) 
 
149 (76.8) 
45 (23.2) 
0.05 0.721 
Tumour size, mm (SD)e 24.1 (12.5) 22.5 (13.2) 0.12 0.064 23.4 (12.8) 23.4 (13.5) 0.00 0.978 
Stage (7th AJCC)f 
  0 
  1A 
  1B 
  2A 
  2B 
  3 
  4 
 
- 
15 (2.9) 
52 (10.0) 
35 (6.7) 
239 (46.1) 
167 (32.2) 
11 (2.1) 
 
5 (1.1) 
64 (14.2) 
123 (27.3) 
52 (11.6) 
131 (29.1) 
68 (15.1) 
7 (1.6) 
0.75 <0.001  
- 
10 (5.2) 
36 (18.6) 
26 (13.4) 
83 (42.8) 
34 (17.5) 
5 (2.6) 
 
- 
14 (7.2) 
43 (22.2) 
24 (12.4) 
69 (35.6) 
43 (22.2) 
1 (0.5) 
0.10 0.271 
pT-stage (7th AJCC)g 
  0 
  1 
  2 
  3 
  4 
 
- 
23 (4.4) 
145 (27.9) 
179 (34.5) 
172 (33.1) 
 
5 (1.1) 
77 (17.1) 
178 (39.6) 
118 (26.2) 
72 (16.0) 
0.62 <0.001  
- 
15 (7.7) 
70 (36.1) 
71 (36.6) 
38 (19.6) 
 
- 
16 (8.2) 
72 (37.1) 
63 (32.5) 
43 (22.2) 
0.01 0.838 
pN-stage (7th AJCC) 
  N0 
  N1 
 
128 (24.6) 
392 (75.4) 
 
258 (56.6) 
198 (43.4) 
0.76 <0.001  
78 (40.2) 
116 (59.8) 
 
88 (45.4) 
106 (54.6) 
0.11 0.305 
Histopathologic subtypeh 
  Intestinal  
  Pancreaticobiliary 
  Mixed 
 
83 (27.1) 
197 (64.4) 
26 (8.5) 
 
139 (49.1) 
119 (42.0) 
25 (8.8) 
0.36 <0.001  
36 (29.5) 
80 (65.6) 
6 (4.9) 
 
55 (45.1) 
60 (49.2) 
7 (5.7) 
0.26 0.032 
Differentiation gradei 
  Well 
  Moderately 
  Poorly 
 
25 (4.9) 
273 (53.4) 
213 (41.7) 
 
51 (11.4) 
275 (61.2) 
123 (27.4) 
0.35 <0.001  
15 (7.7) 
127 (65.5) 
52 (26.8) 
 
16 (8.2) 
123 (63.4) 
55 (28.4) 
0.02 0.914 
Perineural invasionj 
  Present 
  Absent 
 
247 (48.2) 
265 (51.8) 
 
129 (32.3) 
271 (67.8) 
0.37 <0.001  
75 (38.7) 
119 (61.3) 
 
73 (37.6) 
121 (62.4) 
0.02 0.834 
Lymphovascular invasionk 
  Present  
  Absent 
 
354 (69.0) 
159 (31.0) 
 
199 (47.4) 
221 (52.6) 
0.50 <0.001  
108 (55.7) 
86 (44.3) 
 
107 (55.2) 
87 (44.8) 
0.01 0.919 
Data are given as No. (per cent) unless noted otherwise. Missing values unmatched cohort: a3 missing sex, b223 missing ASA 
classification, c257 missing BMI, d4 missing resection margin, e37 missing tumour size, f7 missing overall stage, g7 missing T-class, h387 
missing histopathologic subtype, i16 missing differentiation grade, j64 missing perineural invasion, k40 missing lymphovascular invasion. 
Missing values in the matched cohort: c102 missing BMI, e16 missing tumour size, h144 missing histopathologic subtype. 
 
 
 
The most frequently administered regimen was Gemcitabine monotherapy in 390 (75.7 per cent 
patients, followed by Gemcitabine in combination with Capecitabine in 34 (6.6 per cent patients. The 
proportion of patients completing six cycles was 74 per cent and 91 per cent, respectively. Details on 
all adjuvant chemotherapy regimens, including number of cycles received, are given in supplementary 
Table S2 and S3.  
 
Figure 2. CONSORT diagram 
 
 
Overall survival 
At the end of follow-up, 592 (60.7 per cent) patients were alive with a median follow-up time of 41 
(IQR 18-64) months. The median survival of the complete cohort was 67 (95 per cent confidence 
interval 56-78) months and 1-, 3-, and 5-year overall survival rates were 89 per cent, 63 per cent and 
54 per cent, respectively. There was no survival difference between patients with a histopathologic 
subtype and patients in whom the subtype was missing (67 months; 95 per cent confidence interval 
49-85 months and 65 months; 95 per cent confidence interval 48-82), respectively, p=0.985). 
A total of 194 patients who received adjuvant chemotherapy were matched to 194 patients who had 
no adjuvant chemotherapy (Table 1). Optimal balance was achieved for age, ASA classification, BMI, 
resection margin status, tumour size, overall stage, pT-stage, differentiation grade, perineural invasion 
and lymphovascular invasion. Some degree of unbalance remained for the variables sex, pN-stage and 
histopathologic subtype.  
Figure 3A shows the overall survival of the matched cohort; adjuvant chemotherapy versus no 
adjuvant chemotherapy. Median survival was not reached in the adjuvant chemotherapy group versus 
60 months in the no adjuvant chemotherapy group, p=0.051. Corresponding 1-, 3-, and 5-year overall 
survival rates were 93 per cent, 68 per cent and 62 per cent in the adjuvant chemotherapy group 
versus 86 per cent, 62 per cent and 49 per cent in the no adjuvant chemotherapy group, respectively.  
The Cox proportional hazards model for overall survival is shown in Table 2. Variables associated with 
survival in univariable analysis were age >65 years, R1 resection, pT-stage 3/4, pN-stage 1, 
pancreaticobiliary/mixed subtype, poor tumour differentiation, and lymphovascular- and perineural 
invasion.  
 
Figure 3a. Overall survival by adjuvant chemotherapy,  Figure 3b. Overall survival by adjuvant  
in the matched cohort of all subtypes.   chemotherapy, in the matched cohort of 
pancreaticobiliary/  
        mixed subtype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACT = Adjuvant chemotherapy, NACT = No adjuvant chemotherapy 
 
Multivariable analysis revealed that adjuvant chemotherapy (mono-agent regimen HR=0.70 [95 per 
cent confidence interval 0.50-0.99] p=0.042; multi-agent regimen HR=0.38 [95 per cent confidence 
interval 0.17-0.83, P=0.015) was associated with an improved overall survival after adjusting for other 
variables associated with overall survival. The interaction term pN-stage*Adjuvant chemotherapy was 
not statistically significant in the multivariable Cox model and was therefore removed from the model.  
 
Table 2. Cox proportional hazards model for overall survival in patients with resected AAC. 
 Univariable Multivariable 
 Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value 
Age >65 years 1.392 (1.132 – 1.712) 0.002   
Female sex 1.022 (0.835 – 1.250) 0.834   
ASA 3/4 1.266 (0.973 – 1.649) 0.079   
Adjuvant chemotherapy 
Mono-agent regimena 
Multi-agent regimena 
 
1.209 (0.970 – 1.508) 
1.219 (0.839 – 1.771) 
 
0.092 
0.298 
 
0.699 (0.495 – 0.988) 
0.380 (0.174 – 0.830) 
 
0.042 
0.015 
R1 resection 2.62 (2.09 – 3.29) <0.001 1.473 (1.018 – 2.132) 0.040 
pT-stage 3/4 2.750 (2.199 – 3.39) <0.001   
pN-stage 1 4.02 (3.13 – 5.16) <0.001 3.487 (2.184 – 5.566) <0.001 
Histopathologic subtype 
Pancreaticobiliary/mixedb 
 
1.536 (1.158 – 2.038) 
 
0.003 
  
Tumour differentiation 
Poorlyc 
 
1.849 (1.509 – 2.265) 
 
<0.001 
  
Lymphovascular invasion 2.575 (2.049 – 3.235) <0.001   
Perineural invasion 2.167 (1.755 – 2.676) <0.001 1.657 (1.148 – 2.390) 0.007 
aCompared with no adjuvant chemotherapy. bCompared with intestinal type. cCompared with 
well/moderately differentiated tumour 
 
Pancreaticobiliary and mixed subtype 
Table 3 shows the baseline characteristics of the two matched subgroups. A total of 97 patients with 
pancreaticobiliary/mixed subtype who received adjuvant chemotherapy were matched to 97 
comparable patients who did not receive adjuvant chemotherapy. Optimal balance was obtained for 
sex, ASA classification, BMI, resection margin status, tumour size, overall stage, pN-stage, 
differentiation grade, perineural- and lymphovascular invasion. For age, histopathologic subtype and 
pT-stage some degree of unbalance remained. Figure 3B shows the overall survival of the matched 
cohort; adjuvant chemotherapy versus no adjuvant chemotherapy in the pancreaticobiliary/mixed 
subtype.  
Median survival was not reached in the adjuvant chemotherapy group versus 32 months in the no 
adjuvant chemotherapy group, p=0.020. Corresponding 1-, 3-, and 5-year overall survival rates were 
90 per cent, 66 per cent and 64 per cent in the adjuvant chemotherapy group versus 77 per cent, 49 
per cent and 45 per cent in the no adjuvant chemotherapy group, respectively.  
 
 
 
   
Table 3. Baseline characteristics of the matched pancreaticobiliary/mixed and intestinal subgroups of resected AAC. 
 
 Pancreaticobiliary/mixed subtype Intestinal subtype 
 
 Adjuvant 
chemotherapy 
(N=97) 
No adjuvant 
chemotherapy 
(N=97) 
SMD P value Adjuvant 
chemotherapy 
(N=45) 
No adjuvant 
chemotherapy 
(N=45) 
SMD P value 
Age, years (SD) 68 (9) 69 (9) 0.11 0.431 67 (8) 66 (11) 0.10 0.378 
Female 45 (46.4) 48 (49.5) 0.07 0.666 22 (48.9) 23 (51.1) 0.05 0.833 
ASA classificationa 
  1 
  2 
  3 
  4 
 
17 (21.5) 
39 (49.4) 
22 (27.8) 
1 (1.3) 
 
13 (17.6) 
40 (54.1) 
20 (27.0) 
1 (1.4) 
0.05 0.924  
3 (8.3) 
26 (72.2) 
6 (16.7) 
1 (2.8) 
 
5 (11.9) 
27 (64.3) 
10 (23.8) 
- 
0.03 0.558 
BMI, kg/m2 (SD)b 25.5 (4.3) 25.7 (5.2) 0.04 0.773 27.6 (4.3) 26.1 (5.8) 0.29 0.277 
Resection margin 
  R0 
  R1 
 
73 (75.3) 
24 (24.7) 
 
72 (74.2) 
25 (25.8) 
0.03 0.869  
34 (75.6) 
11 (24.4) 
 
35 (77.8) 
10 (22.2) 
0.07 0.803 
Tumour size, mm (SD)c 22.6 (11.6) 22.6 (9.8) 0.00 0.974 23.2 (12.2) 22.2 (12.2) 0.08 0.708 
Stage (7th AJCC) 
  1A 
  1B 
  2A 
  2B 
  3 
  4 
 
3 (3.1) 
17 (17.5) 
11 (11.3) 
41 (42.3) 
21 (21.6) 
4 (4.1) 
 
1 (1.0) 
16 (16.5) 
13 (13.4) 
38 (39.2) 
27 (27.8) 
2 (2.1) 
0.07 0.742  
4 (8.9) 
11 (24.4) 
3 (6.7) 
16 (35.6) 
11 (24.4) 
- 
 
3 (6.7) 
12 (26.7) 
6 (13.3) 
17 (37.8) 
7 (15.6) 
- 
0.10 0.716 
pT-stage (7th AJCC) 
  1 
  2 
  3 
  4 
 
5 (5.2) 
35 (36.1) 
33 (34.0) 
24 (24.7) 
 
2 (2.1) 
30 (30.9) 
37 (38.1) 
28 (28.9) 
0.18 0.531  
5 (11.1) 
19 (42.2) 
10 (22.2) 
11 (24.4) 
 
3 (6.7) 
21 (46.7) 
14 (31.1) 
7 (15.6) 
0.05 0.541 
pN-stage (7th AJCC) 
  N0 
  N1 
 
35 (36.1) 
62 (63.9) 
 
35 (36.1) 
62 (63.9) 
0.00 1.000  
27 (60.0) 
18 (40.0) 
 
22 (48.9) 
23 (51.1) 
0.24 0.396 
Histopathologic subtype 
  Intestinal 
  Pancreaticobiliary 
  Mixed 
 
- 
89 (91.8) 
8 (8.2) 
 
- 
83 (85.6) 
14 (14.4) 
0.34 0.174  
45 
- 
- 
 
45 
- 
- 
0.00 1.00 
Differentiation 
  Well 
  Moderately 
  Poorly 
 
5 (5.2) 
61 (62.9) 
31 (32.0) 
 
5 (5.2) 
59 (60.8) 
33 (34.0) 
0.04 0.953  
2 (4.4) 
36 (80.0) 
7 (15.6) 
 
2 (4.4) 
34 (75.6) 
9 (20.0) 
0.09 0.858 
Perineural invasion 
  Present 
  Absent 
 
42 (43.3) 
55 (56.7) 
 
46 (47.4) 
51 (52.6) 
0.09 0.564  
14 (31.1) 
31 (68.9) 
 
14 (31.1) 
31 (68.9) 
0.00 1.000 
Lymphovascular invasion 
  Present 
  Absent 
 
61 (62.9) 
36 (37.1) 
 
64 (66.0) 
33 (34.0) 
0.07 0.653  
26 (57.8) 
19 (42.2) 
 
27 (60.0) 
18 (40.0) 
0.05 0.830 
Data are given as No. (per cent) unless noted otherwise. Missing values pancreaticobiliary/mixed subtype: a41 missing ASA 
classification, b44 missing BMI, c3 missing tumour size. Missing values intestinal subtype: a12 missing ASA classification, b24 missing 
BMI, c4 missing tumour size. 
The model for overall survival in the pancreaticobiliary/mixed subtype is shown in Table 4. 
Characteristics associated with overall survival in univariable analysis were age >65 years, R1 
resection, pT-stage 3/4, pN-stage 1, poor tumour differentiation, and lymphovascular- and perineural 
invasion.  Multivariable analysis showed that adjuvant chemotherapy (mono-agent regimen HR=0.66 
[95 per cent confidence interval 0.46-0.94] p=0.021; multi-agent regimen HR=0.36 [95 per cent 
confidence interval 0.17-0.77] p=0.008) was associated with an improved overall survival after 
adjusting for other variables associated with overall survival. The interaction term pN-stage*Adjuvant 
chemotherapy was not statistically significant in the multivariable Cox model and was therefore 
removed from the model. 
 
Table 4. Cox proportional hazards model for overall survival in pancreaticobiliary/mixed subtype of resected 
ampullary adenocarcinoma. 
 Univariable Multivariable 
 Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value 
Age >65 years 1.420 (1.023 – 1.973) 0.036   
Female sex 0.984 (0.714 – 1.356) 0.922   
ASA 3/4 1.358 (0.887 – 2.078) 0.159   
Adjuvant chemotherapy 
Mono-agent regimena 
Multi-agent regimena 
 
0.904 (0.642 – 1.272) 
0.665 (0.341 – 1.296) 
 
0.563 
0.231 
 
0.655 (0.456 – 0.939) 
0.363 (0.172 – 0.768) 
 
0.021 
0.008 
R1 resection 2.45 (1.75 – 3.42) <0.001 1.511 (1.032 – 2.214) 0.034 
pT-stage 3/4 2.179 (1.484 – 3.200) <0.001   
pN-stage 1 3.69 (2.38 – 5.70) <0.001 2.724 (1.616 – 4.590) <0.001 
Tumour differentiation 
Poorlb 
 
1.572 (1.138 – 2.170) 
 
0.006 
  
Lymphovascular invasion 3.054 (2.016 – 4.627) <0.001 1.635 (1.007 – 2.654) 0.047 
Perineural invasion 2.120 (1.516 – 2.966) <0.001 1.571 (1.063 – 2.320) 0.023 
aCompared with no adjuvant chemotherapy. bCompared with well/moderately differentiated tumour. 
 
Intestinal subtype 
A total of 45 patients with intestinal subtype who received adjuvant chemotherapy were matched to 
45 comparable patients who did not receive adjuvant chemotherapy (Table 3). There was optimal 
balance for the following variables: age, sex, ASA classification, resection margin status, overall stage, 
pT-stage, differentiation grade, perineural invasion and lymphovascular invasion. The groups were not 
well balanced in terms of BMI and pN-stage. Figure 3C shows the overall survival of the matched 
cohort; adjuvant chemotherapy versus no adjuvant chemotherapy in the Intestinal subtype. Median 
survival was not reached in both the adjuvant chemotherapy group and in the no adjuvant 
chemotherapy group, p=0.719. Corresponding 1-, 3-, and 5-year overall survival rates were 95 per 
cent, 71 per cent and 55 per cent in the adjuvant chemotherapy group and 84 per cent, 69 per cent 
and 60 per cent in the no adjuvant chemotherapy group.  
 
Figure 3c. Overall survival by adjuvant chemotherapy, in the matched cohort of intestinal subtype 
 
ACT=Adjuvant chemotherapy, NACT=No adjuvant chemotherapy. 
 
The model for overall survival in intestinal subtype is shown in supplementary Table S4. Associated 
with survival in univariable analysis were R1 resection, pT-stage 3/4, pN+, and lymphovascular- and 
perineural invasion. After adjusting for these variables, adjuvant chemotherapy, both mono or multi 
agent regimen, was not found to be associated with overall survival. The interaction term pN-
stage*Adjuvant chemotherapy was not statistically significant in the multivariable Cox model and was 
therefore removed from the model. 
 
DISCUSSION 
In this study, patients with the pancreaticobiliary or mixed subtype of resected ampullary 
adenocarcinoma had a survival benefit from an adjuvant Gemcitabine-based regimen. In lack of 
randomized data, this large international multi-centre cohort study used propensity scores to match 
patients. In the matched cohort, an improved overall survival was found in patients who received 
adjuvant chemotherapy compared with patients who did not receive chemotherapy. The benefit from 
adjuvant treatment was only seen in patients with the pancreaticobiliary or mixed subtype, but not in 
the intestinal subtype. 
A plausible explanation why survival benefit was noted only in the pancreaticobiliary or mixed subtype 
and not in intestinal subtype, is the choice of the adjuvant chemotherapy regimen, which was 
Gemcitabine monotherapy in the vast majority. Gemcitabine may be effective in pancreatic cancer24, 
however, it is not known for its efficacy in intestinal cancer25. Moreover, intestinal subtype ampullary 
adenocarcinoma showed no sensitivity to Gemcitabine in vitro, whereas a significant growth reduction 
was seen in the pancreaticobiliary subtype26. To date, no clear guidelines or protocols exist on 
adjuvant chemotherapy in ampullary adenocarcinoma, consequently, the decision remains at the 
discretion of the treating oncologist. Until now, most evidence on the efficacy of adjuvant 
chemotherapy in ampullary adenocarcinoma derives from subgroup analyses of the ESPAC-3 trial. The 
92 patients with ampullary adenocarcinoma treated with Gemcitabine in that study had a median 
survival of 70.8 months compared with 57.8 months in the 100 patients treated with 5-FU versus 40.6 
months in the 105 patients who did not receive adjuvant chemotherapy15. This subgroup analysis 
failed to show a statistically significant difference, potentially due to a type II error. Subgroup analyses 
on the different histopathologic subtypes were not performed. The ESPAC-4 trial, comparing 
Gemcitabine alone with doublet Gemcitabine and Capecitabine, has extended recruitment for the 
periampullary cohort27.  
Similar to the current study, a German retrospective mono-centre study of 95 patients with resected 
ampullary adenocarcinoma, demonstrated a survival benefit in patients receiving adjuvant 
Gemcitabine in the pancreaticobiliary subtype only (median survival of 32 months in the Gemcitabine 
group versus 13 months in the patients not receiving adjuvant chemotherapy, P=0.013). However, 
groups were small (22 patients received Gemcitabine vs 24 controls) and no matching was performed, 
resulting in high risk of treatment allocation bias28.  
It is possible that patients with intestinal subtype ampullary adenocarcinoma might benefit from 
adjuvant chemotherapy regimens comparable to those in duodenal cancer. Although the evidence 
regarding adjuvant chemotherapy in duodenal cancer is limited, a survival benefit of 16 months 
(median survival of 42 versus 26 months) has been described in lymph node positive duodenal cancer. 
However, details on specific adjuvant chemotherapy regimens are lacking29. Another retrospective 
study reported an increased survival after adjuvant chemotherapy in the subgroup of patients with a 
lymph node ratio of 0.1 or above30. The ongoing BALLAD trial, investigating different adjuvant 
chemotherapy regimens in small bowel adenocarcinoma, may provide more evidence on this issue31. 
Even though the importance of classifying the different subtypes has been highlighted repeatedly28,32–
34, it appears that documentation of subtype is often lacking. In the current study the histopathologic 
subtype was not reported in 387/976 patients, nearly 40%, suggesting that subtype classification is 
either not considered or remains challenging35. The current study reveals that histopathologic 
subtyping of ampullary adenocarcinoma has potential therapeutic implications and therefore, every 
effort should be made to classify ampullary adenocarcinoma, especially prior to the administration of 
adjuvant chemotherapy.   
Several studies have suggested that additional immunohistochemical staining may improve distinction 
between subtypes35–37. Potential markers expressed in intestinal type carcinoma include CK20, MUC2 
and CDX238–40.  Whereas, pancreaticobiliary type carcinomas are likely to express CK7 and MUC139,40. 
Ang and colleagues have shown that combining morphologic classification with an 
immunohistochemical panel of MUC1, MUC2, CDX2 and CK20 may improve consensus diagnosis35. 
Moreover, Overman and colleagues performed gene expression and proteomic analysis on fresh 
frozen samples of 14 patients with ampullary adenocarcinoma. Two subgroups were identified, an 
intestinal like and pancreaticobiliary like subtype41.  
In addition to the missing values of histopathologic subtype, there are a number of limitations to this 
study. First, due to the retrospective study design, the adjuvant chemotherapy group was selected, 
demonstrated by the more advanced overall stage and unfavourable tumour characteristics in the 
adjuvant chemotherapy group. By using propensity score matching, based on clinical and 
histopathologic variables associated with survival, treatment allocation bias was minimized. However, 
treatment allocation bias can only be entirely avoided by randomization. Second, no central 
histopathology review was done and, consequently differences in subtypes classification between 
centres might have occurred. Even though the WHO classification21 was used in all centre, the use of 
immunohistochemistry was not routine practice but only used on occasion. Indication for the use of 
immunohistochemistry might have different between centres. With improved differentiation of 
subtypes, the observed differences in survival may possibly increase. Third, tumour staging was 
performed using the 7th edition of AJCC, instead of the current 8th edition. The majority of specimens 
in this study were assessed when the 7th edition was in use and restaging would require formal 
revision of all specimens. This was not feasible due to the large cohort and multi-centre aspect of the 
study. Further, N-stage was not optimally balanced between de adjuvant chemotherapy group and 
the no adjuvant chemotherapy group in the matched cohort of all subtypes and in the matched cohort 
of the intestinal subtype. As N-stage was associated with survival, this could have led to an 
underestimated survival benefit in the cohort of all subtypes. In the intestinal subtype, the estimated 
effect of adjuvant chemotherapy on survival could have been overestimated. However, no difference 
was seen in survival between adjuvant chemotherapy and no adjuvant chemotherapy. Possibly, 
adjuvant chemotherapy could have an unfavourable effect on survival in patients with intestinal 
subtype. Lastly, a number of centres from different geographical settings participated in the study. 
This could have resulted in substantial heterogeneity regarding treatment strategy. The inclusion of 
several centres may also however, have improved the external validity of this study. 
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